Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 12/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12697558 | 1.00 | TRPV1 (0.39) | TRPV1PDE2AHDAC1HDAC8HDAC6 | |
| SCHEMBL12697453 | 0.92 | PDE2A (0.42) | PDE2A | |
| SCHEMBL1984584 | 0.92 | PDE2A (0.42) | PDE2A | |
| SCHEMBL12563539 | 0.88 | PDE2A (0.43) | PDE2AHDAC1HDAC8HDAC6WDR5 | |
| SCHEMBL12604757 | 0.87 | PDE2A (0.41) | PDE2AHDAC1HDAC8HDAC6WDR5 | |
| SCHEMBL1987338 | 0.86 | PDE2A (0.46) | PDE2AHDAC1HDAC8HDAC6 | |
| SCHEMBL12603911 | 0.86 | PDE2A (0.46) | PDE2AHDAC1HDAC8HDAC6 | |
| SCHEMBL12697446 | 0.86 | PDE4B (0.45) | HDAC1HDAC8HDAC6 | |
| SCHEMBL1660566 | 0.86 | PDE4B (0.45) | HDAC1HDAC8HDAC6 | |
| SCHEMBL1989719 | 0.86 | PDE2A (0.42) | TRPV1PDE2AHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885PDE2A 1939/4885HDAC1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.